FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308495641> ?p ?o ?g. }

• W4308495641 endingPage "370" @default.
• W4308495641 startingPage "354" @default.
• W4308495641 abstract "Idiopathic thrombocytopenic purpura is a chronic autoimmune hematological disease caused by an increased destruction of platelets and associated thrombocytopenia, for the treatment of which the imported drug romiplostim is used. Сreation of the drug biosimilar provides a reduction in the cost of therapy and an access for the treatment to more patients. The aim of the study was to compare the safety indicators of the reference drug and its biosimilar in vivo and in vitro. Materials and methods. In the in vitro study, a model of “complement-dependent cytotoxicity” induced by the complement was formed on the 32D hTPOR clone 63-cell line, followed by a cell viability measurement with the CellTitter Glo ® kit . An in vivo part of the study was carried out on Javanese macaque monkeys (Macaca fascicularis). During the experiment, the clinical condition, mortality, appetite of the animals, their body weight, body temperature, respiratory rate were assessed, the clinical parameters of blood and urine of the animals were also monitored, and the hemostasis indicators were additionally measured. Results. In the in vitro experiment, the original drug romiplostim and its biosimilar GP40141 were compared in terms of EC50 values. The indicatirs did not show complement-dependent cytotoxicity. According to the in vivo results, no deviations were recorded in the clinical status of the animals and their feed intake, and no lethality was fixed out in the groups either. For all the parameters studied (body weight and temperature, respiratory rate, clinical urinalysis, clinical and biochemical blood tests, coagulation hemostasis), GP40141 and romiplostim, when administered at the doses equivalent to 10 toxic doses (TDs), had comparable effects. Conclusion. In the comparison of safety performance both in vitro and in vivo , the original drug romiplostim and its biosimilar GP40141 showed similar results." @default.
• W4308495641 created "2022-11-12" @default.
• W4308495641 creator A5004162430 @default.
• W4308495641 creator A5009071256 @default.
• W4308495641 creator A5029272501 @default.
• W4308495641 creator A5035030551 @default.
• W4308495641 creator A5040457645 @default.
• W4308495641 creator A5055735513 @default.
• W4308495641 creator A5063416659 @default.
• W4308495641 creator A5068572962 @default.
• W4308495641 creator A5081229552 @default.
• W4308495641 date "2022-10-30" @default.
• W4308495641 modified "2023-10-18" @default.
• W4308495641 title "SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR" @default.
• W4308495641 cites W1940859004 @default.
• W4308495641 cites W1980002878 @default.
• W4308495641 cites W1981693350 @default.
• W4308495641 cites W1983944754 @default.
• W4308495641 cites W1984580814 @default.
• W4308495641 cites W2020910729 @default.
• W4308495641 cites W2060064772 @default.
• W4308495641 cites W2072429146 @default.
• W4308495641 cites W2119920607 @default.
• W4308495641 cites W2141247392 @default.
• W4308495641 cites W2153670291 @default.
• W4308495641 cites W2158803162 @default.
• W4308495641 cites W2163100333 @default.
• W4308495641 cites W2403246139 @default.
• W4308495641 cites W2726273490 @default.
• W4308495641 cites W2915557171 @default.
• W4308495641 cites W2973908960 @default.
• W4308495641 cites W3013438321 @default.
• W4308495641 cites W3015587704 @default.
• W4308495641 cites W3164945230 @default.
• W4308495641 cites W4200381906 @default.
• W4308495641 cites W4246105717 @default.
• W4308495641 doi "https://doi.org/10.19163/2307-9266-2022-10-4-354-370" @default.
• W4308495641 hasPublicationYear "2022" @default.
• W4308495641 type Work @default.
• W4308495641 citedByCount "0" @default.
• W4308495641 crossrefType "journal-article" @default.
• W4308495641 hasAuthorship W4308495641A5004162430 @default.
• W4308495641 hasAuthorship W4308495641A5009071256 @default.
• W4308495641 hasAuthorship W4308495641A5029272501 @default.
• W4308495641 hasAuthorship W4308495641A5035030551 @default.
• W4308495641 hasAuthorship W4308495641A5040457645 @default.
• W4308495641 hasAuthorship W4308495641A5055735513 @default.
• W4308495641 hasAuthorship W4308495641A5063416659 @default.
• W4308495641 hasAuthorship W4308495641A5068572962 @default.
• W4308495641 hasAuthorship W4308495641A5081229552 @default.
• W4308495641 hasBestOaLocation W43084956411 @default.
• W4308495641 hasConcept C109159458 @default.
• W4308495641 hasConcept C126322002 @default.
• W4308495641 hasConcept C142724271 @default.
• W4308495641 hasConcept C150903083 @default.
• W4308495641 hasConcept C203014093 @default.
• W4308495641 hasConcept C204787440 @default.
• W4308495641 hasConcept C207001950 @default.
• W4308495641 hasConcept C27081682 @default.
• W4308495641 hasConcept C2776915898 @default.
• W4308495641 hasConcept C2777863708 @default.
• W4308495641 hasConcept C2779225474 @default.
• W4308495641 hasConcept C28328180 @default.
• W4308495641 hasConcept C535046627 @default.
• W4308495641 hasConcept C54355233 @default.
• W4308495641 hasConcept C71924100 @default.
• W4308495641 hasConcept C77411442 @default.
• W4308495641 hasConcept C86803240 @default.
• W4308495641 hasConcept C98274493 @default.
• W4308495641 hasConceptScore W4308495641C109159458 @default.
• W4308495641 hasConceptScore W4308495641C126322002 @default.
• W4308495641 hasConceptScore W4308495641C142724271 @default.
• W4308495641 hasConceptScore W4308495641C150903083 @default.
• W4308495641 hasConceptScore W4308495641C203014093 @default.
• W4308495641 hasConceptScore W4308495641C204787440 @default.
• W4308495641 hasConceptScore W4308495641C207001950 @default.
• W4308495641 hasConceptScore W4308495641C27081682 @default.
• W4308495641 hasConceptScore W4308495641C2776915898 @default.
• W4308495641 hasConceptScore W4308495641C2777863708 @default.
• W4308495641 hasConceptScore W4308495641C2779225474 @default.
• W4308495641 hasConceptScore W4308495641C28328180 @default.
• W4308495641 hasConceptScore W4308495641C535046627 @default.
• W4308495641 hasConceptScore W4308495641C54355233 @default.
• W4308495641 hasConceptScore W4308495641C71924100 @default.
• W4308495641 hasConceptScore W4308495641C77411442 @default.
• W4308495641 hasConceptScore W4308495641C86803240 @default.
• W4308495641 hasConceptScore W4308495641C98274493 @default.
• W4308495641 hasIssue "4" @default.
• W4308495641 hasLocation W43084956411 @default.
• W4308495641 hasOpenAccess W4308495641 @default.
• W4308495641 hasPrimaryLocation W43084956411 @default.
• W4308495641 hasRelatedWork W195854409 @default.
• W4308495641 hasRelatedWork W1990453785 @default.
• W4308495641 hasRelatedWork W2009588589 @default.
• W4308495641 hasRelatedWork W2080033839 @default.
• W4308495641 hasRelatedWork W2328012130 @default.
• W4308495641 hasRelatedWork W2886928388 @default.
• W4308495641 hasRelatedWork W2970916347 @default.

• next